Daily defined doses

Consumption of medicaments is usually expressed in terms of number of daily defined doses (ODD) administered, ddd, as set by the World Health Organization [52]. The correlation between M and ddd is expressed by (2) ... 

In a retrospective study the data on fluoroquinolones and other antibacterial drugs, rufloxacin was associated with a reporting rate of 221 reports/daily defined dose/ 1000 inhabitants/day, and the most frequent were psychiatric disorders (278). 

Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been made for methyl parathion. An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure. 

What are the accepted indications for anxiolytics Generally speaking, these medications are given nowadays when a patient suffers from anxiety states or symptoms to such an extent that his daily routine is considerably disrupted. It is quite clear from this formulation that the indications for anxiolytics are less sharply defined than those of the antipsychotics and antidepressants when do anxiety symptoms impair daily routine to an extent that one can speak of considerable disruption And who is to determine whether a disruption is considerable or trivial the patient, the doctor, the relatives ... 

What do all these examples mean They provide successful foundations for companies who have decided through their mission statement and core values that define company culture that their company is going to recognize the associates who build and operate the company on a daily basis. 

For residues (such as cleaning agents) that do not have a defined dose, some measure of toxicity, such as an acceptable daily intake (ADI), is used for residue limit purposes. If the subsequently manufactured product is an in vitro diagnostic (IVD), and has no defined dose, then some evaluation of the effects of target residues on the performance or stability of the IVD product should be performed. These non-dose factors are used only for the Li limit there are no changes for calculation of L2 and L3 limits. 

As noted previously, compendial standards arose from the professions on behalf of the public. There are no attempts at regulation by the USP of the daily application of pharmaceutical technology. USP standards are not to be confused with such concepts as the product description. As addressed below, compendial standards are not manufacturing directions as such and do not constitute the manufacturers release criteria. They define the acceptable article as and when used. 

---